Despite walking away from a PBAC recommendation in April, it appears that Eli Lilly is back at the table.
Despite walking away from a PBAC recommendation in April, it appears that Eli Lilly is back at the table.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.